Is NCT06918990 recruiting in Los Angeles, CA?

Yes, NCT06918990 is currently recruiting participants at its Los Angeles, CA location. This kidney transplant rejection clinical trial is actively enrolling qualified participants.

How do I join the kidney transplant rejection clinical trial in Los Angeles?

To join this clinical trial in Los Angeles, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Los Angeles clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Kidney Transplant Rejection Clinical Trial in Los Angeles, CA

About This Kidney Transplant Rejection Study in Los Angeles

The purpose of this study is to see: 1. If using these two drugs (carfilzomib and belatacept) together is safe 2. If the use of these two study drugs in addition to the usual immunosuppression for kidney transplant patients can improve your transplanted kidney function by lowering the antibodies you have against your transplanted kidney 3. If the study drugs effect the immune cells that were responding to your donor kidney. And, whether blood or urine tests can measure signs of inflammation and

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Who Can Participate

Inclusion Criteria

Able to understand and agree to participate in the study.

Have received a kidney transplant from a living or deceased donor (including re-transplants).

Men and women must agree to use birth control during the study and for 3 months after the last dose of study drugs, or be surgically sterile or post-menopausal.

Heart function must be good enough (LVEF of at least 40%) without severe heart issues or high blood pressure in the lungs.

Must have been previously exposed to the Epstein-Barr Virus (EBV).

Diagnosed with specific types of kidney transplant rejection based on criteria, with certain conditions on timing and treatment history.

Kidney function must be at a certain level (eGFR of at least 30 ml/min/1.73 m²).

Patient is ≥6-months post-transplant or is \<6 months post-transplant but has documentation that they have been offered and/or received the local standard of care treatment prior to enrollment.

Must have a measurable level of specific antibodies against the donor kidney (HLA DSA) with a certain intensity.

Up-to-date vaccinations according to guidelines for transplant patients.

Must have a negative tuberculosis (TB) test and chest x-ray before enrollment, no symptoms or known contact with TB, and not have recently traveled to or lived in areas with high TB rates. If previously infected with TB, must have completed treatment and have a recent negative chest x-ray.

If previously infected with COVID-19, must be fully recovered for at least 21 days before joining the study. No COVID-19 test required for those without symptoms.

Exclusion Criteria

Unable or unwilling to give consent or follow study rules.

Kidney transplant with incompatible blood types.

Very high levels of protein in urine, indicating severe kidney issues.

Previously had a non-kidney organ or bone marrow transplant.

Any other medical issues that might increase risk, make following the study rules hard, or affect study results, as judged by the study doctor.

Heart attack within the last year, uncontrolled chest pain, or signs of a recent heart problem on an ECG.

Severe heart failure (Class 3 or higher).

Irregular heartbeats that can't be controlled with medication.

Participants who are actively receiving any of the therapies listed below, or who have previously received these therapies without meeting the required washout period prior to the qualifying biopsy and donor-specific antibody (DSA) assessment:

≥4 weeks since last dose: IVIG (intravenous immunoglobulin), therapeutic plasma exchange (TPE)

≥6 weeks since last dose: Proteasome inhibitors

≥3 months since last dose: Eculizumab; lymphocyte-depleting agents (e.g., rabbit anti-thymocyte globulin, alemtuzumab); anti-CD20 agents

≥6 months since last dose: Anti-CD38 agents; anti-IL-6 agents

Used any experimental drug not specified within the last 4 weeks or longer if the drug stays in the body longer.

Serious medical or mental health issues that could interfere with the study.

Cancer diagnosis or treatment within the past 2 years, except for certain skin cancers or cancers with a high cure rate.

Known allergy to Captisol® (used in the study drug).

Very low blood counts (hemoglobin, neutrophils, or platelets).

Positive for HIV, Hepatitis B, or Hepatitis C, unless Hepatitis C was successfully treated.

Severe infections needing treatment in the last 4 weeks.

Specific kidney infection (BK nephropathy) or high levels of BK virus.

Certain kidney biopsy results indicating other types of rejection or kidney diseases.

Treated for a specific viral infection (CMV) in the last 90 days or resistant to certain CMV treatments.

Received a live vaccine in the last 4 weeks.

Severe liver disease or abnormal liver tests.

Pregnant or breastfeeding women. Women who can become pregnant must have a negative pregnancy test or proof they are not pregnant.

Any other significant medical condition that could interfere with the study according to the doctor.

Kidney rejection within 6 months post-transplant without standard care.

Confirmed severe protein levels in urine.

Underwent certain treatments from the time of entry DSA result and biopsy screening.

History of multiple unprovoked blood clots.

Diagnosed with Atypical Hemolytic Uremic Syndrome (aHUS).

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Los Angeles?

Yes, this clinical trial (NCT06918990) has an active research site in Los Angeles, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Kidney Transplant Rejection Treatment Options in Los Angeles, CA

If you're searching for kidney transplant rejection treatment options in Los Angeles, CA, this clinical trial (NCT06918990) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Los Angeles research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced kidney transplant rejection specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all kidney transplant rejection clinical trials near you to find additional studies recruiting in your area.

Kidney Transplant Rejection Clinical Trial in Los Angeles, CA

Expert Care in Los Angeles

IRB Approved

No-Cost Care

Apply for This Los Angeles Location

Why Participate?

Simple Process